Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA)’s share price fell 4% on Monday . The stock traded as low as $3.07 and last traded at $3.10, with a volume of 100,450 shares changing hands. The stock had previously closed at $3.23.

Several research firms have weighed in on DRNA. Chardan Capital began coverage on Dicerna Pharmaceuticals in a research report on Monday, April 4th. They issued a “neutral” rating and a $5.00 target price for the company. Jefferies Group reaffirmed a “buy” rating and issued a $19.00 target price on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 10th. Stifel Nicolaus dropped their target price on Dicerna Pharmaceuticals from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, May 10th. Cowen and Company reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 10th. Finally, Leerink Swann reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 10th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $11.95.

The company’s market capitalization is $65.91 million. The company has a 50-day moving average price of $3.36 and a 200 day moving average price of $4.94.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.10. On average, analysts predict that Dicerna Pharmaceuticals Inc. will post ($3.34) EPS for the current year.

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.